Program Goal Case Presentation Diane Case Presentation cont ADAEASD Position Statement ADAEASD Position Statement Glycemic Targets ADAEASD Position Statement on Therapeutic Options Lifestyle ID: 710685
Download Presentation The PPT/PDF document "GLP-1 Agonist Clinical Case Challenge: I..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
GLP-1 Agonist Clinical Case Challenge: Intensifying Therapy and Improving Management of T2DSlide2
Program GoalSlide3
Case Presentation: DianeSlide4
Case Presentation (cont)Slide5
ADA/EASD Position StatementSlide6Slide7
ADA/EASD Position Statement: Glycemic TargetsSlide8
ADA/EASD Position Statement on Therapeutic Options: LifestyleSlide9
ADA/EASD Position Statement: A Patient-Centered ApproachSlide10
Informed Medical DecisionSlide11
Considerations for Choice of Antihyperglycemic AgentSlide12
Nonglycemic Effects of MedicationsSlide13
ADA/EASD Position Statement: HypoglycemiaSlide14
Natural History of Type 2 DiabetesSlide15
Beta-Cell Function Deteriorates Over TimeSlide16
Durability of Glycemic Control With Sulfonylurea TherapySlide17Slide18Slide19Slide20Slide21Slide22
HbA1c Reduction of Therapies Added Onto MetforminSlide23
Change in Weight and Hypoglycemia of Therapies Added Onto MetforminSlide24Slide25
Other Considerations: WeightSlide26Slide27Slide28Slide29
Features to Include in a Cost AnalysisSlide30
SulfonylureasSlide31Slide32Slide33Slide34Slide35Slide36
Efficacy of HbA1c
When Added to MetforminSlide37Slide38
Efficacy of GLP-1 Receptor Agonists vs InsulinSlide39Slide40Slide41Slide42Slide43
Pancreatitis: Clinical ImplicationsSlide44
GLP-1 Agonists: Renal ImpairmentSlide45
DPP-4 Inhibitors: Renal ImpairmentSlide46
Liraglutide/Exenatide: Black Box Warning – Risk of Thyroid C-Cell TumorsSlide47
Incretin-Based TherapiesSlide48Slide49Slide50
Treatment of Hyperglycemia Should be IndividualizedSlide51Slide52Slide53